Drug Profile
SCY 635
Alternative Names: SCY-635Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator SCYNEXIS
- Class Antivirals; Ciclosporins
- Mechanism of Action Cyclophilin inhibitors; Hepatitis B virus replication inhibitors; Hepatitis C virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatitis C
- No development reported Hepatitis B
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-B in USA (PO)
- 03 Nov 2014 SCY 635 licensed to Waterstone Pharmaceuticals worldwide
- 25 Apr 2013 Final pharmacodynamics data from preclinical studies presented at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL-2013),,